These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 26839018

  • 1. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B.
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients.
    Viana-Pereira M, Moreno DA, Linhares P, Amorim J, Nabiço R, Costa S, Vaz R, Reis RM.
    Mol Biol Rep; 2020 Feb; 47(2):877-886. PubMed ID: 31721021
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ.
    Carcinogenesis; 2019 Oct 16; 40(10):1229-1239. PubMed ID: 31157866
    [Abstract] [Full Text] [Related]

  • 6. Known glioma risk loci are associated with glioma with a family history of brain tumours -- a case-control gene association study.
    Melin B, Dahlin AM, Andersson U, Wang Z, Henriksson R, Hallmans G, Bondy ML, Johansen C, Feychting M, Ahlbom A, Kitahara CM, Wang SS, Ruder AM, Carreón T, Butler MA, Inskip PD, Purdue M, Hsing AW, Mechanic L, Gillanders E, Yeager M, Linet M, Chanock SJ, Hartge P, Rajaraman P.
    Int J Cancer; 2013 May 15; 132(10):2464-8. PubMed ID: 23115063
    [Abstract] [Full Text] [Related]

  • 7. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
    Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, Sicotte H, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR.
    Neuro Oncol; 2013 Aug 15; 15(8):1041-7. PubMed ID: 23733245
    [Abstract] [Full Text] [Related]

  • 8. Interaction between 5 genetic variants and allergy in glioma risk.
    Schoemaker MJ, Robertson L, Wigertz A, Jones ME, Hosking FJ, Feychting M, Lönn S, McKinney PA, Hepworth SJ, Muir KR, Auvinen A, Salminen T, Kiuru A, Johansen C, Houlston RS, Swerdlow AJ.
    Am J Epidemiol; 2010 Jun 01; 171(11):1165-73. PubMed ID: 20462933
    [Abstract] [Full Text] [Related]

  • 9. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M.
    Cancer; 2006 Oct 15; 107(8):1891-7. PubMed ID: 16986124
    [Abstract] [Full Text] [Related]

  • 10. Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants.
    Qi X, Wan Y, Zhan Q, Yang S, Wang Y, Cai X.
    Mamm Genome; 2016 Feb 15; 27(1-2):1-7. PubMed ID: 26577493
    [Abstract] [Full Text] [Related]

  • 11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ.
    Acta Neuropathol Commun; 2015 Dec 23; 3():88. PubMed ID: 26699864
    [Abstract] [Full Text] [Related]

  • 12. Joint associations between genetic variants and reproductive factors in glioma risk among women.
    Wang SS, Hartge P, Yeager M, Carreón T, Ruder AM, Linet M, Inskip PD, Black A, Hsing AW, Alavanja M, Beane-Freeman L, Safaiean M, Chanock SJ, Rajaraman P.
    Am J Epidemiol; 2011 Oct 15; 174(8):901-8. PubMed ID: 21920947
    [Abstract] [Full Text] [Related]

  • 13. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.
    J Clin Oncol; 2009 Dec 01; 27(34):5743-50. PubMed ID: 19805672
    [Abstract] [Full Text] [Related]

  • 14. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK.
    Oncotarget; 2015 Aug 28; 6(25):20885-901. PubMed ID: 26369702
    [Abstract] [Full Text] [Related]

  • 15. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.
    Oncotarget; 2015 Oct 06; 6(30):30295-305. PubMed ID: 26210286
    [Abstract] [Full Text] [Related]

  • 16. Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue-a glioma-driven study.
    Van der Eecken K, Van der Linden M, Raman L, Creytens D, Dedeurwaerdere F, De Winne K, Ferdinande L, Lammens M, Menten B, Rottiers I, Van Gaever B, Van den Broecke C, Van de Vijver K, Van Roy N, Verbeke S, Van Dorpe J.
    Virchows Arch; 2022 Mar 06; 480(3):677-686. PubMed ID: 35034191
    [Abstract] [Full Text] [Related]

  • 17. Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas.
    Pessôa IA, Amorim CK, Ferreira WAS, Sagica F, Brito JR, Othman M, Meyer B, Liehr T, de Oliveira EHC.
    Int J Mol Sci; 2019 May 30; 20(11):. PubMed ID: 31151164
    [Abstract] [Full Text] [Related]

  • 18. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
    Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, McCoy L, O'Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson AL, Smirnov I, Tihan T, Wiemels J, Yang P, Wiencke JK.
    Nat Genet; 2009 Aug 30; 41(8):905-8. PubMed ID: 19578366
    [Abstract] [Full Text] [Related]

  • 19. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.
    J Neurooncol; 2017 Nov 30; 135(2):273-284. PubMed ID: 28884377
    [Abstract] [Full Text] [Related]

  • 20. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M.
    Br J Cancer; 2014 Nov 11; 111(10):2024-32. PubMed ID: 25314060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.